Mid-term results of autoinjection therapy for erectile dysfunction

Of over 300 patients with erectile dysfunction, 186 were selected
for intracavernosal autoinjection therapy with a standardized
papaverine-phentolamine mixture. A total of 156 patients performed
4,813 protocol autoinjections with a minimum of 10 and a maximum of
230 per patient. The dose that induced a full erection at the
hospital could be reduced under home conditions by a mean of 35 per
cent. Systemic side effects were not observed. The most
inconvenient local side effects were prolonged erections in 24
patients in diagnostic use and in 3 patients in therapeutic use.
These were treated easily without further consequences.